Chlamydia vaccines: recent developments and the role of adjuvants in future formulations

References

• Stephens RS, Tam MR, Kuo C-C, Nowinski RC. Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization. J. Immunol.128, 1083–1089 (1982).
   PubMed Web of Science ®Google Scholar
• Stephens RS, Wagar EA, Schoolnik GK. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med.167, 817–831 (1988).
   PubMed Web of Science ®Google Scholar
• Bandea CI, Kubotaa K, Brown TM et al. Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein (omp1). Sex. Transm. Infect.77, 419–422 (2001).
   PubMed Web of Science ®Google Scholar
• Bush RM, Everett KD. Molecular evolution of Chlamydiaceae. Int. J. Syst. Evol. Microbiol.51, 203–220 (2001).
   PubMed Web of Science ®Google Scholar
• Schachter J, Stephens RS, Timms P et al. Radical changes to chlamydial taxonomy are not necessary just yet. Int. J. Syst. Evol. Microbiol.51, 251–253 (2001).
   Google Scholar
• Schachter J. Infection and disease epidemiology. In Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. Stephens RS (Ed.). ASM, Washington, DC, USA 139–169 (1999).
   Google Scholar
• WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. WHO, Geneva, Switzerland (2001).
   Google Scholar
• CDC. Sexually transmitted diseases, treatment guidelines, 2010. MMWR Recomm. Rep.59(RR-12), 1–110 (2010).
   PubMedGoogle Scholar
• Mahdi OS, Byrne GI, Kalayoglu M. Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Expert Opin. Ther. Patents11, 1253–1265 (2001).
   Web of Science ®Google Scholar
• Schachter J. NAATs to diagnose Chlamydia trachomatis genital infection: a promise still unfulfilled. Expert Rev. Mol. Diagn.1(2), 137–144 (2001).
   PubMedGoogle Scholar
• Thein J, Zhao P, Liu H et al. Does clinical diagnosis indicate chlamydial infection in areas with a low prevalence of trachoma? Ophthalmic Epidemiol.9, 263–269 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson RE, Newhall WJ, Papp JR et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections – 2002. MMWR Recomm. Rep.51, 1–40 (2002).
   PubMedGoogle Scholar
• Rees E. Treatment of pelvic inflammatory disease. Am. J. Obstet. Gynecol.138, 1042–1047 (1980).
   PubMed Web of Science ®Google Scholar
• Westrom L, Joesoef R, Reynolds G et al. Pelvic inflammatory inflammatory disease and infertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopy results. Sex. Transm. Dis.19, 185–192 (1992).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Wolner-Hanssen P. Chlamydia trachomatis: a major threat to reproduction. J. Hum. Reprod.4, 111–124 (1989).
   PubMed Web of Science ®Google Scholar
• Stamm WE, Guinan ME, Johnson C et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N. Engl. J. Med.310, 545–549 (1984).
   PubMed Web of Science ®Google Scholar
• Schachter J, Osoba AO. Lymphogranuloma venereum. Br. Med. Bull.39, 151–154 (1983).
   PubMedGoogle Scholar
• Mabey D, Peeling RW. Lymphogranuloma venereum. Sex. Transm. Infect.78, 90–92 (2002).
   PubMedGoogle Scholar
• Nieuwenhuis RF, Ossewaarde JM, Gotz HM et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar L2 proctitis in The Netherlands among men who have sex with men. Clin. Infect. Dis.39, 996–1003 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Sexually transmitted disease surveillance, 2000. US Department of Health and Human Services, CDC, Atlanta, GA, USA (2001).
   Google Scholar
• Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr. Opin. HIV AIDS5, 305–310 (2010).
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Rutherford G. Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Databse Syst. Rev. (2), CD001220 (2001).
   Google Scholar
• Kilmarx PH, Mock PA, Levine WC. Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretion. Sex. Transm. Dis.28, 347–348 (2001).
   PubMed Web of Science ®Google Scholar
• Mcclelland RS, Wang CC, Mandaliya K et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS15, 105–110 (2001).
   PubMed Web of Science ®Google Scholar
• Simonetti A, Melo J, de Souza P et al. Immunological’s host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes Infect.11, 435–442 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar S, Hammerschlag M. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin. Infect. Dis.44, 568–576 (2007).
   PubMed Web of Science ®Google Scholar
• Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev.8, 451–461 (1995).
   PubMed Web of Science ®Google Scholar
• Gaillat J. Clinical manifestations of Chlamydia pneumoniae infections. Revue de Med. Interne.17, 987–999 (1996).
   PubMed Web of Science ®Google Scholar
• Everett KD. Chlamydia and Chlamydiales: more than meets the eye. Vet. Microbiol.75, 109–126 (2000).
   PubMed Web of Science ®Google Scholar
• Saikku P, Wang SP, Kleemola M et al. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J. Infect. Dis.151, 832–839 (1985).
   PubMed Web of Science ®Google Scholar
• Rodolaki A, Salinas J, Papp J. Recent advances on ovine chlamydial abortion. Vet. Res.29, 275–288 (1998).
   PubMed Web of Science ®Google Scholar
• Nietfeld J. Chlamydial infections in small ruminants. Vet. Clin. North Am. Food Anim. Pract.17, 301–314 (2001).
   PubMedGoogle Scholar
• West S. Global elimination of blinding trachoma by 2020: where are we? Ophthalmic Epidemiol.16, 205 (2009).
   PubMed Web of Science ®Google Scholar
• Brunham R, Rekart M. The arrested immunity hypothesis and the epidemiology of Chlamydia control. Sex. Transm. Dis.35, 53–54 (2008).
   PubMed Web of Science ®Google Scholar
• Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J. Eur. Acad. Dermatol. Venereol.15, 405–409 (2001).
   PubMed Web of Science ®Google Scholar
• Byrne GI. Chlamydial treatment failures: a persistent problem? J. Eur. Acad. Dermatol. Venereol15, 381 (2001).
   PubMed Web of Science ®Google Scholar
• Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother.44, 3288–3297 (2000).
   PubMed Web of Science ®Google Scholar
• Miyashita N, Fukano H, Hara H, Yoshida K, Niki Y, Matsushima T. Recurrent pneumonia due to persistent Chlamydia pneumoniae infection. Intern. Med.41, 30–33 (2002).
   PubMed Web of Science ®Google Scholar
• Rees E, Tait IA, Hobson D, Karayiannis P, Lee N. Persistence of chlamydial infection after treatment for neonatal conjunctivitis. Arch. Dis. Child.56, 193–198 (1981).
   PubMed Web of Science ®Google Scholar
• Babalola OE, Bage SD. The persistence of chlamydial inclusions in clinically quiescent trachoma. West Afr. J. Med.11, 55–61 (1992).
   PubMedGoogle Scholar
• Thejls H, Gnarpe J, Lundkvist O, Heimer G, Larsson G, Victor A. Diagnosis and prevalence of persistent Chlamydia infection in infertile women: tissue culture, direct antigen detection, and serology. Fertil. Steril.55, 304–310 (1991).
   PubMed Web of Science ®Google Scholar
• Dean D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis.182, 909–916 (2000).
   PubMed Web of Science ®Google Scholar
• Smith A, Munoz B, Hsieh YH, Bobo L, Mkocha H, West S. OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzania village women. Ophthalmic Epidemiol.8, 127–135 (2001).
   PubMedGoogle Scholar
• Holm SO, Jha HC, Bhatta RC et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Organ.79, 194–200 (2001).
   PubMed Web of Science ®Google Scholar
• Diamant J, Benis R, Schachter J et al. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol.8, 109–117 (2001).
   PubMedGoogle Scholar
• Bain DL, Lietman T, Rasmussen S et al. Chlamydial genovar distribution after community wide antibiotic treatment. J. Infect. Dis.184, 1581–1588 (2001).
   PubMed Web of Science ®Google Scholar
• Dawson CR, Schachter J. Should trachoma be treated with antibiotics? Lancet359, 184–185 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen CR, Brunham RC. Pathogenesis of Chlamydia induced pelvic inflammatory disease. Sex. Transm. Infect.75, 21–24 (1999).
   PubMed Web of Science ®Google Scholar
• Ssemanda E, Munoz B, Harding-Esch E et al. Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl. Trop. Dis.4(2), e838 (2010).
   PubMedGoogle Scholar
• de la Maza MA, de la Maza LM. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine13, 119–127 (1995).
   PubMed Web of Science ®Google Scholar
• Schachter J. Overview of Chlamydia trachomatis infection and the requirements for a vaccine. Rev. Infect. Dis.7, 713–716 (1985).
   PubMedGoogle Scholar
• Schachter J, Dawson CR. The epidemiology of trachoma predicts more blindness in the future. Sex. Transm. Dis. Suppl.69, 55–62 (1990).
   Google Scholar
• Brunham R, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol.5, 149–161 (2005).
   PubMed Web of Science ®Google Scholar
• Rockey D, Wang J, Lei L, Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines8(10), 1365–1377 (2008).
   Web of Science ®Google Scholar
• Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Vet. J.171, 263–275 (2006).
   PubMed Web of Science ®Google Scholar
• Chalmers WS, Simpson J, Lee SJ, Baxendale W. Use of a live chlamydial vaccine to prevent ovine enzootic abortion. Vet. Rec.141, 63–67 (1997).
   PubMed Web of Science ®Google Scholar
• Grayston JT, Woolridge RL, Wang S et al. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proc. Soc. Exp. Biol. Med.112, 589–595 (1963).
   PubMed Web of Science ®Google Scholar
• Woolridge RL, Grayston JT, Chang IH, Yang CY, Cheng KH. Long-term follow-up of the initial (1959–1960) trachoma vaccine field trial on Taiwan. Am. J. Ophthalmol.63, 1650–1655 (1967).
   Web of Science ®Google Scholar
• Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am. J. Ophthalmol.63, 1615–1620 (1967).
   PubMed Web of Science ®Google Scholar
• Clements C, Dhir S, Grayston J, Wang S. Long term follow-up study of a trachoma vaccine trial in villages of Northern India. Am. J. Ophthalmol.87, 350–353 (1979).
   PubMed Web of Science ®Google Scholar
• Grayston JT, Wang SP, Yang YF, Woolridge RL. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J. Exp. Med.115, 1009–1022 (1962).
   PubMed Web of Science ®Google Scholar
• Bietti G, Guerra P, Vozza R et al. Results of large-scale vaccination against trachoma in East Africa (Ethiopia) 1960–1965. Am. J. Ophthalmol.61, 1010–1029 (1966).
   PubMed Web of Science ®Google Scholar
• Sowa S, Sowa J, Collier L, Blyth W. Trachoma vaccine field trials in The Gambia. J. Hyg. (Lond.)67, 699–717 (1969).
   PubMedGoogle Scholar
• Cochrane M, Armitage C, O’Meara C, Beagley K. Towards a Chlamydia trachomatis vaccine: how close are we? Future Microbiol.5(12), 1833–1856 (2010).
   PubMed Web of Science ®Google Scholar
• de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Investig. Drugs3, 980–986 (2002).
   PubMedGoogle Scholar
• Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol.1, 116–130 (2008).
   PubMed Web of Science ®Google Scholar
• Hafner L, McNeilly C. Vaccines for Chlamydia infections of the female genital tract. Future Microbiol.3(1), 67–77 (2008).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, He Q, Eko FO et al. Development of vaccines to prevent chlamydial STDs. Mucosal Immunol.Update13, 12–17 (2005).
   Google Scholar
• Stephens RS. Chlamydial Genomics and Vaccine Antigen Discovery. J. Infect. Dis.181, S521–S523 (2000).
   PubMed Web of Science ®Google Scholar
• Stephens RS, Lammel CJ. Chlamydia outer membrane protein discovery using genomics. Curr. Opin. Microbiol.4, 16–20 (2001).
   PubMed Web of Science ®Google Scholar
• Kawa DE, Stephens RS. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J. Immunol.168, 5184–5191 (2002).
   PubMed Web of Science ®Google Scholar
• Murdin AD, Dunn P, Sodoyer R et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis.181, S544–S551 (2000).
   PubMed Web of Science ®Google Scholar
• Donati M, Sambri V, Comanducci M et al. DNA immunzation with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. Vaccine21, 1089–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma J, Bosnic AM, Piper JM, Zhong G. Human antibody responses to a Chlamydia-secreted protease factor. Infect. Immun.72, 7164–7171 (2004).
   PubMed Web of Science ®Google Scholar
• Belland RJ, Scidmore MA, Crane DD et al.Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. PNAS98, 13984–13989 (2001).
   PubMed Web of Science ®Google Scholar
• Slepenkin A, de la Maza LM, Peterson EM. Interaction between components of the Type III secretion system of Chlamydiaceae. J. Bacteriol.187, 473–479 (2005).
   PubMed Web of Science ®Google Scholar
• Meoni E, Faenzi E, Frigimelica E et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect. Immun.77, 4168–4176 (2009).
   PubMed Web of Science ®Google Scholar
• Follmann F, Olsen A, Jensen K et al. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J. Infect. Dis.197(6), 897–905 (2008).
   PubMed Web of Science ®Google Scholar
• Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect. Immun.70, 2741–2751 (2002).
   PubMed Web of Science ®Google Scholar
• Loomis PW, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr. Opin. Microbiol.5, 87–91 (2002).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccine: strategies and status. BioDrugs16, 19–35 (2002).
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Eko FO, He Q et al. Delivery of Chlamydia vaccines. Expert Opin. Drug Deliv.2, 549–562 (2005).
   PubMedGoogle Scholar
• Rank RG. Models of immunity. In: Chlamydia: Intracellular Biology, Pathogenesis and Immunity. Stephens RS (Ed.), ASM Press, Washington, DC, USA 239–295 (1999).
   Google Scholar
• Champion C, Kickhoefer V, Liu G et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS ONE4, e5409 (2009).
   PubMed Web of Science ®Google Scholar
• Childs T, Webley W. In vitro assessment of chlamydial antigen display, delivery and processing by halobacterial gas vesicles. Presented at: 2011 ASM General Meeting, New Orleans, LA, USA, Session 197; Abstract 2215 (2011).
   Google Scholar
• Stuart E, Morshed F, Sremac M, DasSarma S. Antigen presentation using novel particulate organelles from halophilic archaea. J. Biotechnol.88, 119–128 (2001).
   PubMedGoogle Scholar
• Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev. Vaccines2(1), 129–146 (2003).
   PubMedGoogle Scholar
• Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal challenge. Infect. Immun.70, 4812–4817 (2002).
   PubMed Web of Science ®Google Scholar
• Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine21, 1455–1465 (2003).
   PubMed Web of Science ®Google Scholar
• Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol.17, 1075–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Schijns VEJC. Antigen delivery systems and immunostimulation. Vet. Immunol. Immunopathol.87, 195–198 (2002).
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Rock KL. Fully mobilizing host defense: building better vacines. Nat. Biotechnol.16, 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Green BA, Baker SM. Recent advances and novel strategies in vaccine development. Curr. Opin. Microbiol.5, 483–488 (2002).
   PubMed Web of Science ®Google Scholar
• Fletcher MA. Vaccine candidate in STD. Int. J. STD AIDS12, 419–422 (2001).
   PubMedGoogle Scholar
• Igietseme JU, Eko FO, He Q, Bandea C, Black C. Developing effective delivery systems for Chlamydia vaccines. Curr. Opin. Mol. Therapeutics6, 182–194 (2004).
   PubMedGoogle Scholar
• Glenn G. The ‘perfect’ adjuvant, a stronger voice. Expert Rev. Vaccines10(4), 399–400 (2011).
   PubMed Web of Science ®Google Scholar
• Schijns VEJC, Lavelle E. Trends in vaccine adjuvants. Expert Rev. Vaccines10(4), 539–550 (2011).
   PubMed Web of Science ®Google Scholar
• O’Hagan D, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines10(4), 447–462 (2011).
   PubMed Web of Science ®Google Scholar
• Raghunandan R. Virus-like particles: innate immune stimulators. Expert Rev. Vaccines10(4), 409–411 (2011).
   PubMed Web of Science ®Google Scholar
• Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev. Vaccines10(4), 437–466 (2011).
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6, 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines10(4), 471–486 (2011).
   PubMed Web of Science ®Google Scholar
• Tomai M, Vasilakos J. TLR-7 and TLR-8 agonists as vaccine adjuvants. Expert Rev. Vaccines10(4), 405–407 (2011).
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines10(4), 499–511 (2011).
   PubMed Web of Science ®Google Scholar
• Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science283, 1335–1339 (1999).
   PubMed Web of Science ®Google Scholar
• Segal B, Chang J, Shevach E. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol.164(11), 5683–5688 (2000).
   PubMed Web of Science ®Google Scholar
• Petrovsy N, Cooper P. Carbohydrate-based immune adjuvants. Expert Rev. Vaccines10(4), 523–537 (2011).
   PubMedGoogle Scholar
• Wu H-Y, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res.16, 187–201 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly KA, Rank RG. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect. Immun.65, 5198–5208 (1997).
   PubMed Web of Science ®Google Scholar
• Staats HF, Montgomery SP, Palker TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses13, 945–952 (1997).
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune respose against a genital challenge. Infect. Immun.69, 6240–6247 (2001).
   PubMed Web of Science ®Google Scholar
• He Q, Martinez-Sobrido L, Eko FO et al. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology122, 28–37 (2007).
   PubMed Web of Science ®Google Scholar
• Li W, Murthy A, Guentzel M et al. Antigen-specific CD4+ T cells produce sufficient IFN-γ to mediate robust protective immunity against genital Chlamydia muridarum infection J. Immunol.180, 3375–3382 (2008).
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun.65, 3361–3369 (1997).
   PubMed Web of Science ®Google Scholar
• Stephens R. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol.11, 44–51 (2003).
   PubMed Web of Science ®Google Scholar
• Gondek D, Roan N, Starnbach M. T cell responses in the absence of IFN-γ exacerbate uterine infection with Chlamydia trachomatis. J. Immunol.183, 1313–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol. Immunol.51, 1139–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Ley K, Smith E, MA S. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res.34, 229–242 (2006).
   PubMed Web of Science ®Google Scholar
• Byrne G. Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity. J. Infect. Dis.201, S126–S133 (2010).
   Google Scholar
• Bachmaier K, Penninger J. Chlamydia and antigenic mimicry. Curr. Top. Microbiol. Immunol.296, 153–163 (2005).
   PubMed Web of Science ®Google Scholar
• Swanborg R, Boros D, Whittum-Hudson J, Hudson A. Molecular mimicry and horror autotoxicus: do chlamydial infections elicit autoimmunity? Expert Rev. Mol. Med.8(29), 1–23 (2006).
   PubMedGoogle Scholar
• Cragnolini J, García-Medel N, de Castro J. Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis. Mol. Cell Proteomics8, 1850–1859 (2009).
   PubMedGoogle Scholar